FDA Panel Backs Experimental Drug To Treat Heart Rhythms

By: Associated Press Email
By: Associated Press Email

Stay up-to-date with KAKE News:

Wednesday, March 18, 2009

A panel of cardiology experts recommends that an experimental drug from Sanofi-Aventis be approved to treat irregular heart rhythms linked to stroke.

The Food and Drug Administration's cardiology drug panel voted 10 to 3 in favor of approving the drug Multaq for that use. The drug is designed to treat atrial fibrillation, a condition that interferes with the beating of the heart's upper chambers.

The FDA is not required to follow the group's advice, though it usually does. The agency is scheduled to make a final decision on the drug by April 30.

If approved, Multaq would be the first new treatment for atrial fibrillation in more than 25 years.

Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus
KAKE TV 1500 N. West Street Wichita, KS 67203-1323 (316) 943-4221
Gray Television, Inc. - Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability 41457767 - kake.com/a?a=41457767